Clinical Trial Update: Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of imatinib (Gleevec) with irinotecan (Camptosar) and cisplatin (Paraplatin) in previously untreated extensive-stage s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Gleevec (Imatinib)
• Paraplatin (Carboplatin)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED